Dr. Nader Pourhassan, CytoDyn’s president and CEO, said:
“Investigators from several sites have requested continued access to PRO 140 to allow patients to continue deriving clinical benefit and maintain HIV-1
viral suppression after the end of treatment in the CD02 Phase 3 combination therapy study. Seven patients have entered the rollover study to receive
continued access to PRO 140 after the completion of the 25-week treatment period in this study. Additionally, 10 patients in the ongoing Phase 2b extension
arm of Monotherapy trial have shown suppressed viral load for two years.”